![Johnny Zou](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Johnny Zou
Direktor/Vorstandsmitglied bei Accession Therapeutics Limited
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bent K. Jakobsen | M | - |
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | - |
Nicholas Cross | M | - |
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | - |
Hans Ivar Robinson | M | 57 |
Accession Therapeutics Limited
![]() Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 3 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Johnny Zou
- Persönliches Netzwerk